Clinical trial · Interventional
DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer
NCT06755866CI-TRIAL-00084281recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To prospectively collect medical images and clinical data related to esophageal cancer using 4D Free Breathing DCE-MRI technology, to evaluate the image quality in the diagnosis of esophageal cancer, and to predict the efficacy of preoperative neoadjuvant chemoradiotherapy for esophageal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Application of DCE-MRI based on 4D Free Breathing in predicting the efficacy of preoperative neoadju
- description
- Prospective collection uses a Philips 3.0T MRI scanner equipped with a dStream Torso 32-channel coil. DCE-MRI was performed using a free respiration sequence with a flow rate of 3.0 m/s. The medical images and clinical data related to esophageal cancer using 4D Free Breathing DCE-MRI technology were performed by two radiologists (one with 3 years of diagnostic experience and the other with 15 years of diagnostic experience), including subjective and objective assessment of image quality in the diagnosis of esophageal cancer, and the use of this technology to predict the efficacy of preoperative neoadjuvant chemoradiotherapy for esophageal cancer with pathological PCR as the outcome.
- interventionNames
- Diagnostic Test: The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer
Primary outcomes (1)
- measure
- Tumor response assessment
- timeFrame
- Surgery was performed within one month after neoadjuvant therapy, and the pathological pCR of the pathological results obtained from the surgery was used as the gold standard in this study to evaluate tumor treatment response
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Be 18 years of age and older; 2. First diagnosis of esophageal squamous cell carcinoma confirmed by histopathological biopsy; 3. The clinical stage is cT1b\~cT2N+; or the clinical stage is cT3\~cT4 any N, (thoracic esophageal cancer, esophagogastric junction cancer); 4. There are no contraindications to MRI examination Exclusion Criteria: 1. Have other primary tumors; 2. The image quality does not meet the diagnostic criteria; 3. Those who do not cooperate with the inspection; 4. Patients who have received prior chemoradiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.